Lipocine to Present at Ladenburg Thalmann 2022 Healthcare Conference

SALT LAKE CITY, September 22, 2022 /PRNewswire/ — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on leveraging its proprietary Lip’ral platform to advance therapeutics through effective oral delivery through the development of differentiated products relative to the standard of care expand, announced today that it will be presenting at the 2022 Thalmann Health Conference in Ladenburg 09/29 in new York.

(PRNews photo/Lipocine Inc.)

(PRNews photo/Lipocine Inc.)

Investors interested in arranging a 1×1 meeting at the conference should contact their Thalmann representative in Ladenburg.

About Lipocin

Lipocine is a biopharmaceutical company using its proprietary technology platform to advance therapeutics with effective oral delivery and to develop products for CNS disorders. Lipocine has candidates in development and candidates for which we are evaluating partnerships targeting large addressable markets with significant unmet medical needs. Our candidates stand for enabling patient-friendly oral delivery options for a favorable risk-benefit profile.

Also Read :  At-Home Service Platforms Reshape Nigeria Healthcare

Candidates for Lipocine clinical development include: LPCN 1154, oral brexanolone, for the potential treatment of postpartum depression, LPCN 2101 for the potential treatment of epilepsy, and LPCN 1148, an oral prodrug of bioidentical testosterone targeted at treating symptoms related to cirrhosis of the liver. Lipocine is exploring partnerships with LPCN 1144, our candidate for treating non-cirrhotic NASH, LPCN 1148, LPCN 1107, our candidate for preventing preterm birth, and LPCN 1111, a candidate for once-daily testosterone replacement therapy (TRT). TLANDO, a novel oral testosterone prodrug containing testosterone undecanoate developed by Lipocine, is FDA approved for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. Visit for more information.

Also Read :  Compassionate Allowances Program: Eligibility, How to Apply

Forward-Looking Statements

This press release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that contain statements that are not historical facts regarding Lipocine’s product candidates and related clinical trials, the achievement of Clinical trial milestones and completion, the timing and completion of regulatory reviews, clinical trial results of our product candidates, the potential uses and benefits of our product candidates, and our product development efforts. Investors are cautioned that all of these forward-looking statements involve risks and uncertainties, including but not limited to the risks that the FDA will not approve any of our products, risks associated with our products, anticipated product benefits not being realized, clinical and regulatory Expectations and unrealized plans, new regulatory developments and requirements, risks related to the FDA approval process, including obtaining regulatory approvals, the results and timing of clinical studies, patient acceptance of Lipocine’s products, the manufacture and marketing of Lipocine’s products and other risks detailed in Lipocine’s filings with the SEC, including but not limited to Form 10-K and other reports on Forms 8-K and 10-Q, all of which are available on the SEC’s website at www.sec .gov are available. Except as required by law, Lipocine undertakes no obligation to publicly update or revise any forward-looking statements contained in this press release.

Also Read :  US offers new details on plan to cap Russian oil prices –


View original content to download multimedia:

SOURCE Lipocine Inc.

Source link